```markdown
---
application_number: "212501Orig1s000"
drug_name: "Cyclophosphamide Injection"
dosage_forms: 
  - "500 mg/2.5 mL"
  - "1 g/5 mL"
sponsor: "Ingenus Pharmaceuticals, LLC"
sponsor_agent: "Ricon Pharma, LLC"
contact_person: "Mukteeshwar Gande"
contact_title: "Chief Scientific Officer"
address: "100 Ford Road, Suite #9, Denville, NJ 07834"
submission_date: "2018-09-27"
complete_response_dates:
  - "2019-07-18"
  - "2020-01-14"
regulatory_contact: 
  name: "Fatima Rizvi, PharmD"
  phone: "(240) 402-7426"
  email: "Fatima.Rizvi@fda.hhs.gov"
signatory: 
  name: "Amna Ibrahim, MD"
  title: "Deputy Director, Division of Oncology 1, Center for Drug Evaluation and Research"
enclosures: 
  - "Labeling"
  - "Carton/Container Labeling"
---

## Critical Data

| Field                         | Information                                                                 |
|------------------------------|------------------------------------------------------------------------------|
| Application Number           | 212501Orig1s000                                                              |
| Drug Name                    | Cyclophosphamide Injection                                                  |
| Dosage Forms                 | 500 mg/2.5 mL, 1 g/5 mL                                                      |
| Sponsor                     | Ingenus Pharmaceuticals, LLC                                                |
| Agent                        | Ricon Pharma, LLC                                                           |
| Contact Person               | Mukteeshwar Gande, Chief Scientific Officer                                 |
| Submission Date              | September 27, 2018                                                           |
| Amendment Dates              | July 24, 2019 (Complete Response), December 26, 2019 (Not Reviewed)         |
| Complete Response Letters    | July 18, 2019, January 14, 2020                                             |
| Regulatory Project Manager   | Fatima Rizvi, PharmD                                                        |
| Contact Email                | Fatima.Rizvi@fda.hhs.gov                                                    |
| Contact Phone                | (240) 402-7426                                                               |
| Signatory                    | Amna Ibrahim, MD, Deputy Director                                           |
| Division                     | Oncology 1, Center for Drug Evaluation and Research                         |
| Enclosures                   | Labeling, Carton/Container Labeling                                         |
| Draft Labeling Note          | 21 pages withheld                                                           |

---

# CENTER FOR DRUG EVALUATION AND RESEARCH

## APPLICATION NUMBER: 212501Orig1s000  
### OTHER ACTION LETTERS

**NDA 212501**  
**COMPLETE RESPONSE**  
**Ingenus Pharmaceuticals, LLC**  
c/o Ricon Pharma, LLC  
Attention: Mukteeshwar Gande, Chief Scientific Officer  
100 Ford Road, Suite #9  
Denville, NJ 07834

---

Dear Dr. Gande:

Please refer to your new drug application (NDA) dated September 27, 2018, received September 27, 2018, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Cyclophosphamide Injection, 500 mg/2.5 mL and 1 g/5 mL.

We acknowledge receipt of your amendment dated July 24, 2019, which constituted a complete response to our July 18, 2019, action letter.

We also acknowledge receipt of your amendment dated December 26, 2019, which was not reviewed for this action. You may incorporate applicable sections of the amendment by specific reference as part of your response to the deficiencies cited in this letter.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

---

## FACILITY INSPECTIONS

During a recent inspection of the manufacturing facility for this application, our field investigator observed objectionable conditions at the facility and conveyed that information to the representative of the facility at the close of the inspection.

Satisfactory resolution of the observations is required before this application may be approved. In response to this deficiency, provide a statement from the facility stating that all issues have been resolved. **Do not** submit actual inspectional correspondence to this application.

---

## PRESCRIBING INFORMATION

Your proposed Prescribing Information (PI) must conform to the content and format regulations found at **21 CFR 201.56(a) and (d)** and **201.57**.

As you develop your proposed PI, we encourage you to review the labeling review resources on the following websites:

1. [PLR Requirements for Prescribing Information](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm)
2. [Pregnancy and Lactation Labeling Final Rule](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm)

These resources include:

- The Final Rule (Physician Labeling Rule) on the content and format of the PI for human drug and biological products
- The Final Rule (Pregnancy and Lactation Labeling Rule) on the content and format of information in the PI on pregnancy, lactation, and females and males of reproductive potential
- Regulations and related guidance documents
- A sample tool illustrating the format for Highlights and Contents
- The Selected Requirements for Prescribing Information (SRPI) − a checklist of important format items from labeling regulations and guidances
- FDA’s established pharmacologic class (EPC) text phrases for inclusion in the Highlights Indications and Usage heading

Submit draft labeling that addresses our proposed revisions in the attached labeling. Prior to resubmitting, use the SRPI checklist to correct any formatting errors to ensure conformance with the related regulations and guidance.

Submit updated content of labeling under **21 CFR 314.50(l)(1)(i)** in Structured Product Labeling (SPL) format as described at:

- [Structured Product Labeling Information](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

To facilitate review:

- Provide a highlighted or marked-up copy that shows all changes, with annotations that support any proposed changes
- Provide a clean Word version

---

## CARTON AND CONTAINER LABELING

Submit draft carton and container labeling revised, as attached, based on our proposed revisions.

---

## SAFETY UPDATE

When responding to the above deficiencies, include a safety update as described at **21 CFR 314.50(d)(5)(vi)(b)**. The safety update should include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level. Include:

1. Description of any significant changes or findings in the safety profile.
2. For discontinuations due to adverse events, serious adverse events, and common adverse events:
   - Present new safety data from studies/clinical trials using the same format as the original submission.
   - Present tabulations of new safety data combined with original application data.
   - Include tables comparing frequency of adverse events in original vs. new combined data.
   - Provide separate tables for other indications.
3. Retabulate reasons for premature trial discontinuation, incorporating new trial drop-outs. Describe any new trends or patterns.
4. Provide case report forms and narrative summaries for each patient who:
   - Died during a clinical trial
   - Did not complete a trial due to an adverse event
   - Experienced serious adverse events
5. Describe any changes in the incidence of common but less serious adverse events.
6. Provide updated clinical exposure information (e.g., number of subjects, person time).
7. Summarize worldwide safety experience, including updated estimates of drug use in other countries.
8. Provide English translations of current approved foreign labeling not previously submitted.

---

## OTHER

Within one year from the date of this letter, you are required to:

- Resubmit the application, or
- Take other actions available under **21 CFR 314.110**

If you do not, we may consider your lack of response a request to withdraw the application under **21 CFR 314.65**.

You may request an extension of time for resubmission.

A resubmission must:

- Fully address all deficiencies in this letter
- Be clearly marked with **"RESUBMISSION"** in large, bold font at the start of the cover letter
- State clearly it is a complete response

**Partial responses will not be processed as a resubmission and will not initiate a new review cycle.**

You may request a meeting or teleconference to discuss further steps necessary for approval. Submit your request in accordance with the draft guidance for industry:  
*Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products*.

The drug product may not be legally marketed until you have been notified in writing that this application is approved.

---

If you have any questions, contact:  
Fatima Rizvi, PharmD, Regulatory Project Manager  
Phone: (240) 402-7426  
Email: Fatima.Rizvi@fda.hhs.gov

---

**Sincerely,**  
Amna Ibrahim, MD  
Deputy Director  
Division of Oncology 1  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

**Enclosures:**

- Labeling  
- Carton/Container Labeling  

> 21 Page(s) of Draft Labeling have been Withheld in Full

---

## Signature

> This is a representation of an electronic record that was signed electronically.

**/s/**  
**AMNA IBRAHIM**  
01/14/2020 11:04:24 AM

---

## ADDITIONAL LETTER

**NDA 212501**  
**COMPLETE RESPONSE**  
**Ricon Pharma, LLC**  
Agent for Ingenus Pharmaceuticals, LLC  
Attention: Mukteeshwar Gande, Chief Scientific Officer  
100 Ford Road, Suite #9  
Denville, NJ 07834

---

Dear Mr. Gande:

Please refer to your NDA dated September 27, 2018. We have reviewed the application and determined that we cannot approve it in its present form for the following reasons:

### FACILITY INSPECTIONS

Deficiencies observed at the manufacturing facility must be resolved before approval.

### PRESCRIBING INFORMATION

As outlined previously, review the following:

1. [PLR Requirements for Prescribing Information](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm)
2. [Pregnancy and Lactation Labeling Final Rule](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm)

Submit labeling in SPL format as described [here](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Include both:

- Highlighted or marked-up copy with annotations  
- Clean Word version

### CARTON AND CONTAINER LABELING

Submit revised draft labeling based on the attached.

### OTHER

You must act within one year of this letter in accordance with **21 CFR 314.110**. If no action is taken, your application may be subject to withdrawal under **21 CFR 314.65**.

A complete resubmission must be clearly marked as such and address all items in this letter. Partial responses will not trigger a review cycle.

If needed, request a meeting via the draft guidance on *Formal Meetings Between FDA and Sponsors or Applicants of PDUFA Products*.

You may not market the drug until formal written approval is issued.

---

If you have any questions, contact:  
Fatima Rizvi, PharmD, Regulatory Project Manager  
Phone: (240) 402-7426  
Email: Fatima.Rizvi@fda.hhs.gov

---

**Sincerely,**  
Amna Ibrahim, MD  
Deputy Director  
Division of Oncology Products 1  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

**Enclosures:**

- Labeling  
- Carton/Container Labeling  

> 21 Page(s) of Draft Labeling have been Withheld in Full

---

## Signature

> This is a representation of an electronic record that was signed electronically.

**/s/**  
**AMNA IBRAHIM**  
07/18/2019 12:36:44 PM
```